Antithrombin activity of surface-bound heparin studied under flow conditions.
Polyacrylamide-grafted polyetherurethane sheets were modified by end-point and multipoint attachment of heparin. The surface-bound heparin was firmly attached. No release of heparin activity could be detected when the surface was rinsed at a wall shear rate of 2000 s-1. Uptake of antithrombin and thrombin inactivation were investigated under well-defined flow conditions by the use of a spinning device with an attached disk-shaped heparinized surface. It is demonstrated that the rate of thrombin inactivation at the antithrombin-heparin surface equals the maximal rate of transport of thrombin toward the surface when the surface coverage of antithrombin exceeds 10 pmol/cm2. This result indicates that a higher intrinsic catalytic efficiency of a surface does not necessarily result in a higher antithrombin activity. We varied the heparin content of the surfaces between 0 and 35 micrograms/cm2 by increasing the number of functional groups to which heparin could be covalently attached. The uptake of antithrombin increased with the heparin content of the surface, but the stoichiometry decreased from 2 to 0.5 pmol antithrombin/micrograms heparin. Apparently, antithrombin could not bind to heparins buried in the poly(acrylamide) layer. The rate of thrombin inactivation at surfaces with low heparin content (2 micrograms/cm2) fells below the transport limit of thrombin and became proportional with the heparin content of the surface. Although the contribution of surface-bound heparin to the neutralization of fluid-phase thrombin was found to be negligible compared with the effect of fluid-phase antithrombin at physiologic relevant concentrations, these heparinized surfaces markedly delayed the onset of thrombin generation in platelet-rich plasma.(ABSTRACT TRUNCATED AT 250 WORDS)
Lindhout
T
T
Biomaterials and Polymer Research Institute (Bioprime), University of Limburg, The Netherlands.
Blezer
R
R
Schoen
P
P
Willems
G M
GM
Fouache
B
B
Verhoeven
M
M
Hendriks
M
M
Cahalan
L
L
Cahalan
P T
PT
D000991:Antithrombins / Q000032:analysis; D002384:Catalysis; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D010973:Platelet Adhesiveness / Q000187:drug effects; D011140:Polyurethanes; D012996:Solutions; D013499:Surface Properties; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000096:biosynthesis
D000991:Antithrombins; D005343:Fibrinolytic Agents; D011140:Polyurethanes; D012996:Solutions; C115016:polyetherurethane; D006493:Heparin; D013917:Thrombin